
Lundbeck Earnings: Strong Demand For Vyepti Drives Improved Near-Term Outlook
Lundbeck's third-quarter revenue grew 7% at constant exchange rates, driven by continued strength from migraine prevention drug Vyepti. Management raised its 2026 outlook, now expecting revenue growth of 11%-12% and adjusted EBITDA growth of 15%-19% at constant exchange rates.